GLP-1 weight loss boosted job and marriage odds by 27 and 29 points

A new working paper by Harvard economics professor Rebecca Diamond finds that women who started GLP-1s and lost weight saw big gains in two life outcomes that depend on outsiders making fast judgments. In the data, non-working women who started GLP-1s were 27 percentage points more likely to have started a job within 18 months of their weight loss than non-users who wanted to use a GLP-1. And women on GLP-1s were 29 percentage points more likely to have started living with a partner or gotten married over the same 18-month window.

That is the headline number, but the real sting is the pattern around it. Diamond reports that the positive employment effects did not show up as higher earnings or more hours for women who already had jobs. Similarly, women already in partnered relationships were not more likely to stay or leave. Instead, the changes concentrated in new social situations: prospective partners and employers considering applicants who are not employed.

To understand why this matters beyond “dating app vibes,” it helps to zoom out to how GLP-1s became part of the modern labor and social economy. Diamond says she “couldn’t find a paper” on economic and social outcomes of these drugs, so she dug into the data and published a new paper. The analysis compared GLP-1 users, non-users, and people interested in using a GLP-1 but who had not started. In all groups, both the users and the want-to-users had high BMIs, which is crucial because the study is trying to isolate what changes after starting the medication.

Diamond emphasizes that this is just one working paper based on a large survey dataset, and it has not been peer-reviewed. She cautions against treating it as clear causal evidence of weight discrimination. That careful framing matters, because any result like this can be influenced by factors that are hard to fully observe, like broader changes in health, motivation, or circumstances that accompany taking medication. Still, Diamond’s own read of the pattern points toward something uncomfortable but coherent: obesity can be a penalty in society, and it may penalize women disproportionately in social and economic ways.

One of the most important “executive briefing” details is what did not change. Starting a GLP-1 did not appear to help women already working increase their earnings or work more hours. And partnered women were not more likely to stay or leave after starting. That combination pushes attention toward mechanisms tied to first impressions, not workplace performance. In the paper’s description, the “markets that respond” are the ones where someone forms a fresh impression of a woman’s body weight: the employer facing an applicant who is not employed and the prospective partner evaluating a new person. If the first impression already happened long ago, or if weight is embedded in a much richer set of information, the effect is less likely to show up.

Diamond also probes possible explanations. She found no significant mental health changes, and health improvements could only explain part of the boost in employment opportunities. That leaves room for other channels like how strangers perceive body size. The study’s logic is basically: if outsiders update their beliefs when they meet you, then losing weight can change what you are “assumed” to be able to do, or what you are “assumed” to want, even if nothing about your actual skill or productivity changes in the moment. The downside is that these first-impression updates can become a form of gatekeeping.

For boards and senior leadership teams, the second-order implication is not just “people judge bodies.” It is that a high-impact medical therapy could interact with social and labor-market biases, and those interactions could amplify inequality. Diamond’s working paper touches on cost and access: in her study, 40% of GLP-1 users were paying out of pocket for the medicine, at about $300/month. She also reports that women who started taking GLP-1s had the highest household incomes, while women who wanted to take GLP-1s but had not started had the lowest. If weight loss reduces economic penalties tied to body size, then unequal access to the medication could mean unequal access to the benefits of that reduced penalty, which could widen gaps between those who can afford GLP-1s and those who cannot.

A final layer: the labor market is where “preference” can become “process.” In dating markets, there may be less moral stigma around traditional beauty standards, but labor markets are different. Diamond frames the paper around the discomfort that, for most jobs, body size should not affect who gets hired, yet the results suggest differences in employment outcomes. The broader context in the source includes a reference to a Society for Human Resource Management survey of about 1,000 human resource professionals in 2023, where about a quarter said obese employees are more likely to be perceived as unmotivated and lazy than slimmer workers. Even if Diamond’s analysis cannot prove discrimination as a cause, it aligns with a world where perception shortcuts influence who gets the shot.

For decision-makers watching talent, culture, benefits, and DEI risk, the strategic stakes are clear: if first impressions drive access to jobs and partnerships, and if GLP-1 access is uneven, then medical innovation can reshape social outcomes and labor outcomes in ways that reinforce existing stratification. The paper is not a policy memo and not peer-reviewed, but it raises a board-level question worth sitting with: in a society where outsiders judge quickly, who is getting the benefit of new therapies, and who is paying the price of delayed access?